Based on LEADER, what do you believe the implications are for the use of liraglutide to mitigate or stabilize diabetic nephropathy? What degree of CV event reduction was observed in patients with CKD?

Based on LEADER, what do you believe the implications are for the use of liraglutide to mitigate or stabilize diabetic nephropathy? What degree of CV event reduction was observed in patients with CKD?

Based on LEADER, what do you believe the implications are for the use of liraglutide to mitigate or stabilize diabetic nephropathy? What degree of CV event reduction was observed in patients with CKD?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Johannes F.E. Mann, MD

Johannes F.E. Mann, MD

Professor of Medicine
University of Erlangen-Nürnberg
Director, Dept. of Nephrology, Hypertension & Rheumatology
Munich General Hospitals
Munich, Germany